MALIGNANCIESMalignancies, some fatal, have been reported in children, adolescents, and young adults treated with TNF blockers, including infliximab products.
The majority of reported cases have occurred in patients with Crohn's disease or ulcerative colitis, and most were in adolescent and young adult males.
In clinical trials of some TNF blockers, including infliximab products, more cases of other malignancies were observed compared with controls.
Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy, including infliximab products.
Discontinue ZYMFENTRA treatment if symptoms of a lupus-like syndrome develop.

ZYMFENTRA ® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs) By Investing.com